rectal cancer

Immunotherapy Drug Anti-Programmed Cell Death Protein 1 Dostarlimb Has 100% Efficacy Rate Against A Subset of Rectal Cancer [Study]

Medicine & Technology Jun 05, 2022

A promising study shows that dostarlimab was effective in phase II clinical trials of a dozen patients with a subset of rectal cancer. Read on to learn more.

rectal cancer

Immunotherapy Drug Anti-Programmed Cell Death Protein 1 Dostarlimb Has 100% Efficacy Rate Against A Subset of Rectal Cancer [Study]

Most Popular

How Technology Is Changing the Real Estate Industry?

How a Plant-Based Diet Can Protect Against Breast Cancer: Insights from Nutrition Research

Study Reveals High Turnover in Scientific Research Careers: What This Means for Future Scientists

Nikolay Karpenko Biography, Photo, Career, Accomplishments

Why It's So Difficult to Lose Weight: The Biological Explanation Behind Obesity

Recommended Stories

NASA Shuts Down Voyager 2 Science Instrument After 47 Years to Conserve Energy

OpenAI’s Whisper Faces Scrutiny Over Accuracy, Experts Find 'Hallucinated' Text in Transcripts

Martian Ice May Support Microbial Life Beneath Its Surface, New Study Suggests

NASA Astronaut Hospitalized After Returning from Extended Space Mission